| 16th Feb 2023 7:00 am |
RNS |
Cancellation - 4d Pharma Plc |
| 15th Feb 2023 1:16 pm |
RNS |
Cancellation of admission to trading on AIM |
| 2nd Feb 2023 3:10 pm |
RNS |
Updated Results from Renal Cell Carcinoma Cohort |
| 16th Jan 2023 10:15 am |
RNS |
Result of Meeting |
| 30th Dec 2022 12:30 pm |
RNS |
Update on Administration and Suspension of Trading |
| 16th Nov 2022 7:00 am |
RNS |
Blautix Phase II Clinical Trial Results Published |
| 10th Nov 2022 2:00 pm |
RNS |
MRx0518 SITC 2022 poster presentations |
| 5th Oct 2022 1:00 pm |
RNS |
MRx0518 poster presentations at SITC 2022 |
| 29th Sep 2022 10:00 am |
RNS |
Update on Suspension of Trading on AIM |
| 24th Aug 2022 7:00 am |
RNS |
Publication of preclinical autism research |
| 4th Aug 2022 3:33 pm |
RNS |
Publication of Joint Administrators' Proposals |
| 1st Jul 2022 5:33 pm |
RNS |
Temporary Pause of Recruitment in Clinical Trials |
| 28th Jun 2022 6:28 pm |
RNS |
4D Pharma receives Notice of Delisting from NASDAQ |
| 28th Jun 2022 3:15 pm |
RNS |
Result of AGM |
| 27th Jun 2022 5:30 pm |
RNS |
4D Pharma |
| 24th Jun 2022 6:22 pm |
RNS |
Update on Suspension of Trading |
| 24th Jun 2022 12:30 pm |
RNS |
Temporary Suspension |
| 24th Jun 2022 12:30 pm |
RNS |
Suspension - 4D Pharma PLC |
| 14th Jun 2022 7:00 am |
RNS |
Pre AGM-Investor Presentation and Q&A |
| 7th Jun 2022 11:00 am |
RNS |
Exercise of Options and Total Voting Rights |
| 27th May 2022 7:00 am |
RNS |
ASCO 2022 MRx0518 and Bavencio Trial In Progress |
| 25th May 2022 1:51 pm |
RNS |
Annual Report and Notice of AGM |
| 17th May 2022 7:00 am |
RNS |
ATS 2022 - MRx-4DP0004 Phase I/II Part A poster |
| 1st Apr 2022 7:00 am |
RNS |
Final Results |
| 24th Mar 2022 10:50 am |
RNS |
Holding(s) in Company |
| 23rd Mar 2022 7:00 am |
RNS |
MRx0518 + Keytruda - Primary endpoint met in RCC |
| 21st Mar 2022 10:46 am |
RNS |
Holding(s) in Company |
| 9th Mar 2022 7:00 am |
RNS |
Form F3 Registration Statement filed with SEC |
| 24th Feb 2022 7:21 am |
RNS |
Holding(s) in Company |
| 23rd Feb 2022 7:00 am |
RNS |
Participation in Chardan Microbiome Summit |
| 22nd Feb 2022 7:00 am |
RNS |
Parkinson’s trial receives FDA IND clearance |
| 18th Feb 2022 7:00 am |
RNS |
Restatement of Interim Results to June 30, 2021 |
| 27th Jan 2022 7:00 am |
RNS |
Additional MRx04 Phase 1/2 asthma data and event |
| 25th Jan 2022 5:17 pm |
RNS |
Holding(s) in Company |
| 20th Jan 2022 7:00 am |
RNS |
4D pharma to host virtual KOL event |
| 6th Jan 2022 10:07 am |
RNS |
Holding(s) in Company |
| 5th Jan 2022 7:00 am |
RNS |
Participation in Upcoming Investor Conference |
| 4th Jan 2022 7:00 am |
RNS |
4D pharma appoints John Doyle as CFO |
| 4th Jan 2022 7:00 am |
RNS |
Grant of Options |
| 13th Dec 2021 7:00 am |
RNS |
4D pharma Phase 1/2 asthma study Part A results |
